Background: Inhibition of interleukin (IL)-13, a Type 2 inflammatory mediator in asthma, improves lung function\nand reduces exacerbations; however, more effective therapies are needed. A subset of asthma patients also exhibits\nelevated IL-17, which is associated with greater disease severity, neutrophilic inflammation, and steroid resistance.\nBITS7201A is a novel, humanized bispecific antibody that binds and neutralizes both IL-13 and IL-17.\nMethods: Safety, pharmacokinetics, and immunogenicity of BITS7201A were evaluated in a phase 1 study. Part A\nwas a single ascending-dose design with 5 cohorts: 30-, 90-, and 300-mg subcutaneous (SC), and 300- and 750-mg\nintravenous (IV). Part B was a multiple ascending-dose design with 3 cohorts: 150-, 300-, and 600-mg SC every 4\nweeks � 3 doses. Both parts enrolled approximately 8 healthy volunteers into each cohort (6 active: 2 placebo). Part\nB included an additional cohort of patients with mild asthma (600-mg SC).\nResults: Forty-one subjects (31 active, 10 placebo) and 26 subjects (20 active, 6 placebo) were enrolled into Parts A\nand B, respectively. The cohort with mild asthma patients was terminated after enrollment of a single patient. No\ndeaths, serious adverse events, or dose-limiting adverse events occurred. In Part A, 12 active (39%) and 5 placebo\nsubjects (50%), and in Part B, 6 active (30%) and 3 placebo subjects (50%) experienced at least 1 treatmentemergent\nadverse event (TEAE). The most common AEs were fatigue (n = 3) and influenza-like illness (n = 2). One\ninjection-site reaction was reported. Two subjects with elevated blood eosinophil counts at baseline had\ntransient elevations in blood eosinophils����
Loading....